Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the fifteen brokerages that are currently covering the stock, Marketbeat ...

Cytokinetics, Inc. (CYTK) stock saw a modest uptick, ending the day at $50.75 which represents a slight increase of $2.89 or 6.04% from the prior close of $47.86. The stock opened at $47.75 and ...

The FDA has followed the advice of its expert advisors and rejected Cytokinetics’ cardiac myosin activator omecamtiv mecarbil as a treatment for heart failure, saying the efficacy data for the ...

Shares of Duke Energy Co. (NYSE:DUK – Get Free Report) have been given an average recommendation of “Moderate Buy” by the ...